In a fruitful collaboration, 4Mediks, along with the Department of Microbiology at the Ramón y Cajal Hospital led by Dr. Rosa del Campo, has carried out a series of trials that mark a milestone in the fight against antibiotic-resistant pathogens. The results, which have generated great optimism, reveal the high efficacy of the biocidal product developed by 4Mediks, not only in eliminating resistant microorganisms but also in its capacity to not induce additional mutations in them.

In recent decades, antibiotic resistance has become one of the greatest threats to global health, putting at risk the medical advances of the 20th century. The adaptability and evolution of pathogens have made it increasingly difficult to treat infections that were manageable before, leading the scientific community to search for effective and safe alternatives.

4Mediks has developed a biocidal product with a unique mechanism of action, designed to attack resistant pathogens without giving them the opportunity to develop new resistances.

To validate the efficacy of the biocide, 4Mediks and the Ramón y Cajal Hospital conducted a series of trials. These studies included a wide range of pathogens, including those known for their resistance to conventional antibiotic treatments.

the biocidal product from 4Mediks not only effectively eliminated all the resistant pathogens it was tested on but also demonstrated not to induce mutations in the microorganisms. This last point is especially significant, as one of the main concerns in the development of new antimicrobials is the potential to generate additional resistances.

These findings open a new chapter in the fight against antibiotic resistance. The confirmation that the biocidal product from 4Mediks is both effective and safe represents a significant advancement, offering a potentially revolutionary tool in the control of nosocomial infections.